LivaNova (LIVN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Eleven directors are nominated for election, each for a term expiring at the 2027 AGM.
Advisory votes are proposed on U.S. executive compensation (Say on Pay) and the UK directors' remuneration report.
Ratification of PricewaterhouseCoopers LLP as both U.S. and UK statutory auditor for 2026 is proposed.
Authorization is sought for directors to allot shares and grant rights, and to disapply pre-emption rights for certain share issuances.
Approval is requested for share repurchase contracts, allowing buybacks up to 10% of issued shares.
Board of directors and corporate governance
Eleven director nominees are listed, with individual resolutions for each.
Board recommends voting in favor of all nominees and proposals 2-10.
Executive compensation and say-on-pay
Advisory votes are scheduled for both U.S. executive compensation and the UK directors' remuneration report for 2025.
Latest events from LivaNova
- Shareholders will vote on directors, executive pay, auditors, share authority, and ESG initiatives.LIVN
Proxy filing29 Apr 2026 - Double-digit 2025 growth and margin gains set stage for 6–7% revenue growth in 2026.LIVN
Q4 202525 Feb 2026 - Q2 revenue up 10% and adjusted EPS up, with raised 2024 guidance and strong segment growth.LIVN
Q2 20242 Feb 2026 - Twelve key resolutions were presented and 89% of voting rights were represented.LIVN
AGM 20241 Feb 2026 - Core growth, innovation in DTD/OSA, and margin expansion drive a multi-year growth outlook.LIVN
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Sustained growth driven by talent, innovation, and strategic execution, with a 2030 vision.LIVN
Baird 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue up 11.2%, margins expand, and guidance raised on strong segment growth.LIVN
Q3 202417 Jan 2026 - OSA market entry and reimbursement gains drive growth, with profitability targeted by 2029.LIVN
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Strong core growth, promising OSA trial, and strategic R&D shifts support future expansion.LIVN
Stifel 2024 Healthcare Conference13 Jan 2026